Valneva (VALN) announced that the United States Food and Drug Administration, FDA, has suspended the license for IXCHIQ, citing four new reports of serious adverse events, SAEs, consistent with chikungunya-like illness. The suspension of the license is effective immediately and requires Valneva to stop shipping and selling of IXCHIQ in the United States. The suspension follows the FDA’s decision on August 6, 2025 to remove its recommended pause in the use of IXCHIQ in individuals 60 years of age and older based on a thorough investigation of reported SAEs, primarily among elderly individuals with multiple underlying health conditions.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VALN:
- Valneva Faces FDA Suspension of Chikungunya Vaccine License
- Valneva SE (ADR) trading halted, news pending
- Valneva’s Promising Future: Buy Rating Backed by VLA15 Vaccine and Robust Portfolio
- Valneva assumed with a Buy at H.C. Wainwright
- Valneva’s Chikungunya Vaccine IXCHIQ® Gains Health Canada Approval